Concepedia

Publication | Open Access

A phase 1 trial of E7974 administered on day 1 of a 21‐day cycle in patients with advanced solid tumors

DOIFull Paper Access

24

Citations

36

References

2012

Year

Caio Rocha‐Lima, Soley Bayraktar, Jessica MacIntyre, Luis E. Raez, Aurea M. Flores, Annapoorna Ferrell, Eric H. Rubin, Elizabeth Poplin, Antoinette R. Tan, Antonio Lucarelli,
Cancer

Abstract

This study shows that E7974 once every 21-day cycle shows antitumor activity in patients with refractory solid tumors. The recommended phase 2 dose is 0.45 mg/m(2).

References

YearCitations

Page 1